United States Patent:   6,086,922

Assignee:  Oxo Chemie AG (Friborg/Schweiz, CH)

Filed:  March 19, 1993

The present invention is concerned with the use of a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections. The chlorite matrix is an isotonic solution containing 5 to 100 mMol ClO₂- per liter of solution.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide an agent which inactivates HIV viruses in the blood without having a damaging influence on the blood and on the body of the patient.

In accordance with the present invention, there is provided a method of using a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections consisting of an isotonic solution containing 5 to 100 mMol, and preferably 50 to 80 mMol of ClO₂- per liter of solution.

The solution can be used as an injection solution or, after dilution, as an infusion solution.

In accordance with the present invention, there is also provided a method for parenteral treatment of HIV infections comprising administering an inhibition effective amount of a chlorite matrix solution comprising an isotonic solution comprising 5 to 100 mMol of ClO₂- per liter of solution. The method of the present invention causes an inhibition of the infection of undamaged cells as well as a stimulation of T-cells and Natural Killer (NK) cells.

Claim 1 of 13 Claims

1. A method of parenterally treating HIV infections, comprising administering to a subject in need of such treatment an inhibition-effective amount of a chemically-stabilized chlorite matrix comprising an isotonic solution containing about 5 to about 100 mMol ClO₂- per liter of isotonic solution.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.